FI962220A - Transdermaalinen terapeuttinen järjestelmä - Google Patents

Transdermaalinen terapeuttinen järjestelmä Download PDF

Info

Publication number
FI962220A
FI962220A FI962220A FI962220A FI962220A FI 962220 A FI962220 A FI 962220A FI 962220 A FI962220 A FI 962220A FI 962220 A FI962220 A FI 962220A FI 962220 A FI962220 A FI 962220A
Authority
FI
Finland
Prior art keywords
pct
active substance
therapeutic system
transdermal therapeutic
sec
Prior art date
Application number
FI962220A
Other languages
English (en)
Swedish (sv)
Other versions
FI962220A0 (fi
FI122131B (fi
Inventor
Thomas Hille
Walter Mueller
Bodo Asmussen
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6504684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI962220(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of FI962220A0 publication Critical patent/FI962220A0/fi
Publication of FI962220A publication Critical patent/FI962220A/fi
Application granted granted Critical
Publication of FI122131B publication Critical patent/FI122131B/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI962220A 1993-12-10 1996-05-27 Menetelmä transdermaalisen terapeuttisen järjestelmän valmistamiseksi, joka on tarkoitettu myrkyllisen organofosforihermomyrkyn myrkytyksen ennaltaehkäisyyn tai esikäsittelyyn FI122131B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4342174A DE4342174C1 (de) 1993-12-10 1993-12-10 Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
DE4342174 1993-12-10
EP9404048 1994-12-06
PCT/EP1994/004048 WO1995015755A1 (de) 1993-12-10 1994-12-06 Transdermales therapeutisches system zur prophylaxe einer vergiftung durch phosphororganische nervengifte bestehend aus einer wirkstoffkombination von einem parasympathikomimetikum und einem parasympathikolytikum

Publications (3)

Publication Number Publication Date
FI962220A0 FI962220A0 (fi) 1996-05-27
FI962220A true FI962220A (fi) 1996-06-27
FI122131B FI122131B (fi) 2011-09-15

Family

ID=6504684

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962220A FI122131B (fi) 1993-12-10 1996-05-27 Menetelmä transdermaalisen terapeuttisen järjestelmän valmistamiseksi, joka on tarkoitettu myrkyllisen organofosforihermomyrkyn myrkytyksen ennaltaehkäisyyn tai esikäsittelyyn

Country Status (19)

Country Link
US (1) US5939095A (fi)
EP (1) EP0732924B1 (fi)
JP (1) JP3739789B2 (fi)
KR (1) KR100397361B1 (fi)
AT (1) ATE433339T1 (fi)
CA (1) CA2178603C (fi)
CZ (1) CZ291057B6 (fi)
DE (2) DE4342174C1 (fi)
ES (1) ES2329426T3 (fi)
FI (1) FI122131B (fi)
HU (1) HUT74432A (fi)
IL (1) IL111942A (fi)
MY (1) MY111715A (fi)
NO (1) NO962405L (fi)
NZ (1) NZ277492A (fi)
PL (1) PL314914A1 (fi)
SK (1) SK284356B6 (fi)
WO (1) WO1995015755A1 (fi)
ZA (1) ZA949842B (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19743484C1 (de) * 1997-10-01 1999-01-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems
US7011843B2 (en) * 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
AU775914B2 (en) * 1998-12-24 2004-08-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
AU2003228796A1 (en) * 2002-05-01 2003-11-17 Eisai Co., Ltd. Cholinesterase inhibitors to prevent injuries caused by chemicals
DE10301851A1 (de) * 2003-01-17 2004-07-29 Lts Lohmann Therapie-Systeme Ag Verfahren zur medikamentösen Prophylaxe gegen Vergiftungen durch Cholinesterase-Hemmer, sowie hierfür geeignete Wirkstoffe und Arzneimittel
US20050013869A1 (en) * 2003-07-18 2005-01-20 Chaw Cheng Shu Sustained release formulation for carbamates and a method therefor
US8299062B2 (en) * 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
US20070093518A1 (en) * 2003-09-19 2007-04-26 Wetherell Janet R Pharmaceutical compositions for the treatment of organophosphate poisoning
AU2012200612B2 (en) * 2004-09-24 2014-11-20 The Government Of The United States, As Represented By The Secretary Of The Army Method of treating organophosphorus poisoning
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
CN101044200A (zh) 2004-09-24 2007-09-26 巴尔的摩马里兰大学 治疗有机磷中毒的方法
WO2008022365A2 (de) * 2006-08-24 2008-02-28 Sanochemia Ltd. Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel
GB0809905D0 (en) * 2008-06-02 2008-07-09 Secr Defence A Transdermal drug delivery device
RU2612506C2 (ru) 2011-03-03 2017-03-09 Импел Ньюрофарма Инк. Устройство для назальной доставки лекарственных средств
WO2020112766A1 (en) * 2018-11-26 2020-06-04 Steven Hoffman Compositions and methods for treating nerve agent exposure
AU2020276605A1 (en) 2019-05-14 2022-01-20 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
AR207805A1 (es) * 1975-02-06 1976-10-29 Alza Corp Substrato apropiado para formar apositos para la dispensacion continua de escopolamina base por via transdermica
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4278679A (en) * 1980-05-01 1981-07-14 Chromalloy American Corporation Combination of two or more drugs in a single dosage form wherein one of the drugs is a physostigmine compound
US4952586A (en) * 1982-08-27 1990-08-28 The Regents Of The University Of California Edrophonium-atropine composition and therapeutic uses thereof
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US5106831A (en) * 1987-08-13 1992-04-21 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Pharmaceutical composition comprising a spiro oxathiolon/quinuclidine and method of treating senile dementia
US4981858A (en) * 1987-08-13 1991-01-01 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Optical isomers
DE3843239C1 (fi) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE3843238C1 (fi) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
EP0523150A4 (en) * 1990-04-06 1993-09-29 Pharmetrix Corporation Device and method for enhanced administration of physostigmine
DE4115558A1 (de) * 1991-05-13 1992-11-19 Dresden Arzneimittel Prophylaktisches antidot gegen phosphororganische gifte
GB9118028D0 (en) * 1991-08-21 1991-10-09 Secr Defence Brit Improved transdrmal formulations

Also Published As

Publication number Publication date
JPH09506360A (ja) 1997-06-24
CZ291057B6 (cs) 2002-12-11
JP3739789B2 (ja) 2006-01-25
EP0732924A1 (de) 1996-09-25
ATE433339T1 (de) 2009-06-15
ZA949842B (en) 1995-09-01
AU1273395A (en) 1995-06-27
HUT74432A (en) 1996-12-30
ES2329426T3 (es) 2009-11-25
HU9601569D0 (en) 1996-08-28
AU703692B2 (en) 1999-04-01
KR960706339A (ko) 1996-12-09
MY111715A (en) 2000-11-30
KR100397361B1 (ko) 2004-03-24
SK284356B6 (sk) 2005-02-04
US5939095A (en) 1999-08-17
SK73996A3 (en) 1997-01-08
CA2178603C (en) 2005-08-09
FI962220A0 (fi) 1996-05-27
CZ168496A3 (en) 1996-11-13
IL111942A0 (en) 1995-03-15
NO962405D0 (no) 1996-06-07
FI122131B (fi) 2011-09-15
CA2178603A1 (en) 1995-06-15
NO962405L (no) 1996-08-07
IL111942A (en) 1998-02-08
NZ277492A (en) 1998-01-26
EP0732924B1 (de) 2009-06-10
DE4342174C1 (de) 1995-05-11
WO1995015755A1 (de) 1995-06-15
DE59410461D1 (de) 2009-07-23
PL314914A1 (en) 1996-09-30

Similar Documents

Publication Publication Date Title
FI962220A0 (fi) Transdermaalinen terapeuttinen järjestelmä
FI954990A0 (fi) Aktiiviainetta sisältävä transdermaalinen valmiste
SE9301171D0 (sv) Pharmaceutical composition containing lipophilic drugs
DE69619052D1 (de) Feste, wasserfreie, pharmazeutische Zubereitungen für vaginale Verwendung
ATE237331T1 (de) Deuterierte wirkstoffe in transdermaler applikation
PT732926E (pt) Formulacao farmaceutica para a profilaxia ou o pre-tratamento do envenenamento por inibidores de colinesterase organofosforados
DE69705110T2 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
ES2176331T3 (es) Uso de agentes inmunosupresores para el tratamiento de la esquizofrenia.
PT695303E (pt) Sais de piridinio e seu emprego no combate as bacterias helicobacter
AR006437A1 (es) Uso de monohidrocloruro de n-(endo-9-metil-9-azabiciclo [3.3.1]non-3-il)-1- metilimidazol-3-carboxamida, para la fabricacion de un medicamento para eltratamiento o la profilaxis de diarrea y una composicion farmaceutica que lo contiene
FI884041A (fi) Desinfiointikoostumus stafylokokkien tappamiseksi
BR9714785A (pt) Composições desinfetantes e processos de desinfecção de superfìcies

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 122131

Country of ref document: FI

MM Patent lapsed